Esmya® is an oral Selective Progesterone Receptor Modulator (SPRM) characterized by a tissue‑specific partial progesterone antagonist effect1.
Esmya® directly acts on the endometrium, the fibroids and the pituitary gland1.
|Endometrium||Histological changes lead to reduced uterine bleeding|
|Fibroids||Blockade of progesterone receptors, inhibition of cell proliferation and induction of
apoptosis reduces their size
|Pituitary gland||Ovulation is inhibited, LH and FSH secretion is partially suppressed, and mid-follicular
oestrogen levels are maintained
FSH, follicle-stimulating hormone; LH, luteinising hormone